Takeda’s Ninlaro (ixazomib) Receives NICE Recommendation for the Treatment of Multiple Myeloma
Shots:
- Ninlaro (proteasome inhibitor) is recommended by NICE's final appraisal document in combination with lenalidomide & dexamethasone as a treatment option for adult patients with RRMM who have received two or three lines of therapy
- The recommendation was based on the P-III study (TOURMALINE-MM1) results evaluating ixazomib + lenalidomide & dexamethasone vs lenalidomide & dexamethasone with PBO in 722 patients
- The results showed that patients treated with the combination therapy achieved an improvement in clinical outcomes, AEs were consistent with reported safety profiles for the individual agents, and PFS was significantly longer in the ixazomib group vs PBO at a median follow-up of 14.7mos. with m-PFS (20.6 vs 14.7mos.)
Ref: Nice | Image: Takeda
Related News:- Takeda Reports Results of Ninlaro (ixazomib) in a P-III Clinical Study for Newly Diagnosed Multiple Myeloma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
